Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Biliary Tract Diseases

Free Subscription Articles published in Cancer Retrieve available abstracts of 20 articles: HTML format

Single Articles

May 2023
1. JANKU F, Javle MM, Sen S, Pant S, et al
   A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors.
   Cancer. 2023;129:1537-1546.
   PubMed     Abstract available
   
   
   March 2023
2. KEARNEY JF, Weighill D, Yeh JJ
   Promise of bile circulating tumor DNA in biliary tract cancers.
   Cancer. 2023 Mar 18. doi: 10.1002/cncr.34715.
   PubMed    
   
   
   
3. OHYAMA H, Hirotsu Y, Amemiya K, Miura Y, et al
   Comparison of genomic profiling of circulating tumor DNA in pancreaticobiliary malignancies in plasma and bile.
   Cancer. 2023 Mar 18. doi: 10.1002/cncr.34717.
   PubMed     Abstract available
   
   
   January 2023
4. HEMMINKI K, Sundquist K, Sundquist J, Forsti A, et al
   Autoimmune diseases as comorbidities for liver, gallbladder, and biliary duct cancers in Sweden.
   Cancer. 2023 Jan 30. doi: 10.1002/cncr.34663.
   PubMed     Abstract available
   
   
   
5. COFFMAN-D'ANNIBALE KL, Greten TF
   Top advances of the year: Hepatobiliary cancers.
   Cancer. 2023 Jan 24. doi: 10.1002/cncr.34652.
   PubMed     Abstract available
   
   
   
6. KLEIN O, Kee D, Nagrial A, Markman B, et al
   Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?
   Cancer. 2023 Jan 24. doi: 10.1002/cncr.34660.
   PubMed    
   
   
   
7. SAHAI V, Zalupski MM
   Reply to "Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?".
   Cancer. 2023 Jan 24. doi: 10.1002/cncr.34659.
   PubMed    
   
   
   
8. ZHANG J, Huang Q, Yang Y, Zhang J, et al
   A novel prognostic system combining carbonic anhydrase II and preoperative CA19-9 for intrahepatic cholangiocarcinoma after curative resection.
   Cancer. 2023 Jan 10. doi: 10.1002/cncr.34639.
   PubMed     Abstract available
   
   
   December 2022
9. SHRIDHAR R, Blinn P, Huston J, Meredith KL, et al
   Outcomes of adjuvant radiation therapy after chemotherapy in resected extrahepatic cholangiocarcinoma: A National Cancer Database analysis.
   Cancer. 2022 Dec 21. doi: 10.1002/cncr.34625.
   PubMed     Abstract available
   
   
   November 2022
10. ZHENG Y, Huang N, Kuang S, Zhang J, et al
    The clinicopathological significance and relapse predictive role of tumor microenvironment of intrahepatic cholangiocarcinoma after radical surgery.
    Cancer. 2022 Nov 26. doi: 10.1002/cncr.34552.
    PubMed     Abstract available
    
    
    
11. OHAEGBULAM KC, Koethe Y, Fung A, Mayo SC, et al
    The multidisciplinary management of cholangiocarcinoma.
    Cancer. 2022 Nov 16. doi: 10.1002/cncr.34541.
    PubMed     Abstract available
    
    
    August 2022
12. LEE YT, Singal AG, Lauzon M, Agopian VG, et al
    Disparities in curative treatments and outcomes for early stage intrahepatic cholangiocarcinoma in the United States.
    Cancer. 2022 Aug 23. doi: 10.1002/cncr.34436.
    PubMed     Abstract available
    
    
    July 2022
13. SAHAI V, Griffith KA, Beg MS, Shaib WL, et al
    A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01.
    Cancer. 2022 Jul 27. doi: 10.1002/cncr.34394.
    PubMed     Abstract available
    
    
    April 2022
14. DE B, Tran Cao HS, Vauthey JN, Manzar GS, et al
    Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States.
    Cancer. 2022 Apr 13. doi: 10.1002/cncr.34223.
    PubMed     Abstract available
    
    
    November 2021
15. LEE TY, Bates SE, Abou-Alfa GK
    Equipoise, drug development, and biliary cancer.
    Cancer. 2021 Nov 24. doi: 10.1002/cncr.34020.
    PubMed    
    
    
    August 2021
16. XU J, Bai Y, Sun H, Bai C, et al
    A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer.
    Cancer. 2021 Aug 6. doi: 10.1002/cncr.33803.
    PubMed     Abstract available
    
    
    July 2021
17. SNYDER RA
    A noticeable absence.
    Cancer. 2021;127:2397-2398.
    PubMed     Abstract available
    
    
    March 2021
18. OUYANG G, Liu Q, Wu Y, Liu Z, et al
    The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study 2017.
    Cancer. 2021 Mar 22. doi: 10.1002/cncr.33476.
    PubMed     Abstract available
    
    
    December 2020
19. KAMARAJAH SK, Bednar F, Cho CS, Nathan H, et al
    Survival benefit with adjuvant radiotherapy after resection of distal cholangiocarcinoma: A propensity-matched National Cancer Database analysis.
    Cancer. 2020 Dec 15. doi: 10.1002/cncr.33356.
    PubMed     Abstract available
    
    
    
20. TAN ES, Cao B, Kim J, Al-Toubah TE, et al
    Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
    Cancer. 2020 Dec 8. doi: 10.1002/cncr.33364.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Biliary Tract Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: